Liquid Biopsy Market Companies Analysis

The liquid biopsy revolution is no longer a promise on the horizon — it’s a fast-moving industry rewriting how clinicians detect and manage cancer. According to the Renub Research figures provided, the global liquid biopsy market is forecast to grow from US$ 4.29 billion in 2024 to US$ 15.46 billion by 2033, representing a CAGR of 15.30% (2025–2033). That rapid expansion reflects a convergence of rising cancer incidence, advances in genomics and sequencing, and growing appetite for personalized, minimally invasive diagnostics.

Liquid biopsy techniques — analyzing circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells (CTCs), exosomes and other biomarkers in blood or other body fluids — unlock three clinical utilities that drive adoption: earlier detection, real-time monitoring of tumor dynamics, and guidance of targeted therapies. Those clinical wins translate into commercial opportunity: tests that reduce surgical biopsies, speed treatment decisions, and enable longitudinal surveillance fit neatly into value-based care models.

Request Free Sample Report

Why the market is accelerating

Several structural forces underpin the market’s strong compound growth:

Clinical need and patient preference: Minimally invasive blood tests reduce risk and discomfort compared with tissue biopsies and are repeatable for monitoring.

Technological progress: Improved sensitivity of digital PCR and high-throughput NGS panels lets labs detect low allele-frequency variants and complex signatures.

Regulatory advances & reimbursement momentum: More approvals and pilot reimbursement programs are making tests commercially viable in routine oncology workflows.

Precision medicine demand: As targeted agents proliferate, clinicians need rapid, accurate biomarker readouts to match patients to therapies.

Expanding use cases: From MRD (minimal residual disease) to multi-cancer early detection (MCED), the addressable market keeps growing.

Competitive landscape — who’s shaping the field

The liquid biopsy market remains concentrated around diagnostics and genomics leaders that combine assay chemistry, instrumentation, and data science. Below are the major players and what they bring to the table.

Roche Diagnostics (F. Hoffmann-La Roche Ltd.)

A legacy diagnostics powerhouse, Roche brings broad laboratory reach and molecular diagnostics platforms. With deep clinical relationships and integrated workflows, Roche positions itself as a channel partner for labs adopting liquid biopsy testing in oncology.

Guardant Health

A poster child for the sector, Guardant pioneered comprehensive plasma NGS assays (Guardant360, GuardantOMNI) and is pushing into MCED with its Shield program. Strengths: market leadership, extensive IP (reported >230 patents), and strong R&D. Opportunity: broad global expansion of multi-cancer screening; risk: competition on sensitivity and regulatory pathways for screening.

Illumina

Leader in sequencing technology, Illumina supplies the instruments and chemistry powering many liquid biopsy NGS tests. Strengths: unmatched sequencing infrastructure and R&D. Opportunity: expansion into clinical diagnostics and companion testing; risk: pricing pressure and competition from alternative sequencing platforms.

Thermo Fisher Scientific

A diversified life-science behemoth that offers sequencing platforms, consumables, and lab services — appealing to labs that want end-to-end solutions and scale.

Bio-Rad Laboratories

Specializes in digital PCR and other platforms useful for high-sensitivity mutation detection and quantification — key for MRD and targeted monitoring.

Exact Sciences (Genomic Health)

Known for Cologuard, Exact Sciences leverages screening experience and commercial reach to expand molecular oncology offerings beyond stool-based screening into broader diagnostic workflows.

Natera

A leader in cfDNA assays for reproductive and oncology testing. Natera has also emphasized sustainability — cutting kit waste by 31% in 2024 and reducing Scope 1 & 2 emissions — signaling investor and payer-friendly corporate governance.

Labcorp

Labcorp continues to expand its precision oncology portfolio. Notably, in April 2025 it launched Labcorp Plasma Detect (for recurrence risk in stage III colon cancer) and PGDx elio plasma focus Dx, the first FDA-authorized kitted liquid biopsy for pan-solid tumors — moves that broaden payer engagement and lab adoption.

Tempus AI Inc.

In January 2025, Tempus launched xT CDx, an FDA-approved NGS-based IVD with an expansive gene panel aimed at delivering actionable genomic insights to clinicians — illustrating how data-centric companies are entering the regulated diagnostics space.

Biocept, QIAGEN, Caris Life Sciences, Foundation Medicine (Roche), MDxHealth, Epigenomics, Johnson & Johnson (Janssen), and others

Each brings niche capabilities — from QIAGEN’s PAXgene urine collection and QIAamp cfDNA extraction kits to Caris’s integrative tumor profiling and Foundation Medicine’s tissue and plasma genomic services. These complementary strengths (sample stabilization, extraction, informatics) increase the ecosystem’s robustness.

Product and sustainability highlights

QIAGEN offers practical sample stabilization and extraction products — PAXgene Urine Liquid Biopsy Set, QIAamp Circulating Nucleic Acid Kit, and QIAseq cfDNA All-in-One Kit — that streamline preanalytic workflows and improve cfDNA yield for downstream NGS.

Natera’s sustainability efforts (31% kit waste reduction in 2024, My Green Lab certifications for facilities) reflect a growing expectation for ESG performance across diagnostics firms.

Johnson & Johnson has ambitious energy and emissions targets — aiming for 100% renewable electricity in multiple regions by 2024 and net-zero across its value chain by 2045 — which can influence supplier selection and tender decisions in large health systems.

SWOT snapshot (selected leaders)

Guardant Health

Strengths: Market leader with broad test portfolio and IP.

Opportunities: MCED expansion (Shield), global adoption for treatment selection and MRD.

Threats: Regulatory hurdles for screening, competition on price and sensitivity.

Illumina

Strengths: Sequencing technology dominance, platform standardization.

Opportunities: Growth in clinical NGS applications and companion diagnostics.

Threats: Platform competition, pricing erosion, and potential regulatory scrutiny.

Market outlook & implications

Renub Research’s forecast to US$ 15.46 billion by 2033 is plausible given expanding clinical indications (MRD, recurrence monitoring, therapy selection, and screening), technological maturation, and progressively favorable regulatory climates. Key inflection points to watch:

Regulatory approvals for screening tests — successful approvals and demonstrated real-world benefit could unlock mass-market adoption.

Reimbursement decisions — payer policies for MRD and routine monitoring will drive or restrict test utilization in community settings.

Analytical advances — increased sensitivity at low variant allele fractions will expand use in early detection and post-treatment surveillance.

Integration into clinical pathways — seamless data flows and clinical decision support will matter as much as assay performance.

For investors and pharma partners, the sector offers a blend of recurring revenue (laboratory testing volumes) and high-margin service contracts (companion diagnostics, trial support). For clinicians and patients, the promise is more timely, less invasive, and increasingly personalized care.

Final thoughts

Liquid biopsy has moved from niche research tool to clinical mainstay in several oncology niches — and its growth curve is steep. The next five years will test which companies convert scientific promise into durable clinical utility and broad adoption. Those that combine rigorous validation, payer alignment, and scalable workflows — while attending to sustainability and regulatory rigor — will capture the biggest share of Renub Research’s multibillion-dollar forecast. For patients, the payoff is simple but profound: safer, smarter tests that catch disease earlier and guide better care.